how big is Oxygenta Pharma?

As of Jun 06, Oxygenta Pharmaceutical Ltd has a market capitalization of 458.60 Cr, classifying it as a Micro Cap company, with recent net sales of 109.31 Cr and a net profit loss of 10.29 Cr. Shareholder's funds are at -20.12 Cr, with total assets of 54.46 Cr as of Mar 2024.

Market Cap: As of Jun 06, Oxygenta Pharmaceutical Ltd has a market capitalization of 458.60 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which is Standalone data, amounts to 109.31 Cr. In contrast, the sum of Net Profit for the same period is -10.29 Cr, indicating a loss.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar 2024. The Shareholder's Funds are reported at -20.12 Cr, while Total Assets stand at 54.46 Cr.

Who are in the management team of Oxygenta Pharma?

As of March 2022, the management team of Oxygenta Pharma includes Sai Sudhakar Vankineni (Managing Director), D Vidya Sagar, Muralidhar R, Sangari Kondal Reddy, Padmaja Surapureddy (Independent Directors), Kanuganti Raghavender Rao (Executive Director), Sravani Reddy Gantla, Bharath Reddy Guntuku (Additional Directors), and Dolly Mandhan (Company Secretary & Compliance Officer). Each member contributes to the company's governance and operational oversight.

As of March 2022, the management team of Oxygenta Pharma includes the following individuals:<BR><BR>1. Sai Sudhakar Vankineni - Managing Director<BR>2. D Vidya Sagar - Independent Director<BR>3. Muralidhar R - Director (Technical)<BR>4. Sangari Kondal Reddy - Independent Director<BR>5. Padmaja Surapureddy - Independent Director<BR>6. Kanuganti Raghavender Rao - Executive Director<BR>7. Sravani Reddy Gantla - Additional Director<BR>8. Bharath Reddy Guntuku - Additional Director<BR>9. Dolly Mandhan - Company Secretary & Compliance Officer<BR><BR>Each member plays a crucial role in the governance and operational oversight of the company.

Has Oxygenta Pharma declared dividend?

No Dividend History Available

Who are the peers of the Oxygenta Pharma?

Oxygenta Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Oxygenta Pharma has a 1-year return of 169.57%, its peers show varying management risks and growth rates, with Divi's Lab having the highest return at 51.96%.

Peers: The peers of Oxygenta Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Trident Lifeline, Gennex Lab., Sanjiv.Parant., Ambalal Sarabhai, and Sat Kartar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Sanjiv.Parant., while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is noted for Gennex Lab. and Ambalal Sarabhai, while Average management risk is seen at Trident Lifeline and Sat Kartar. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Trident Lifeline, and Sat Kartar, while Below Average growth is noted for Divi's Lab. and Torrent Pharma, and the rest. Oxygenta Pharma does not qualify for any ratings in Management Risk, Growth, or Capital Structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Gennex Lab. at -22.86%. Oxygenta Pharma's 1-year return of 169.57% significantly exceeds both. Additionally, Gennex Lab. and Ambalal Sarabhai have negative six-month returns.

Is Oxygenta Pharma overvalued or undervalued?

As of June 20, 2023, Oxygenta Pharma is considered overvalued and risky due to its negative financial ratios, including a PE ratio of -45.92 and a ROCE of -32.27%, despite a strong stock performance of 284.59% over the past year.

As of 20 June 2023, Oxygenta Pharma's valuation grade has moved from does not qualify to risky, indicating a significant shift in its financial standing. The company appears to be overvalued, given its negative PE ratio of -45.92, an EV to EBITDA ratio of -52.33, and a ROCE of -32.27%. These ratios suggest that the company's earnings and capital efficiency are under severe pressure.<BR><BR>In comparison to its peers, Oxygenta Pharma's valuation metrics are starkly unfavorable. For instance, Sun Pharmaceutical Industries Ltd. has a PE ratio of 35.25, while Cipla Ltd. boasts a PE of 22.99, both indicating a healthier financial position. Additionally, Oxygenta's PEG ratio stands at 0.00, which is significantly lower than the industry averages. Despite its recent stock performance, which has outpaced the Sensex with a 1-year return of 284.59% versus 7.60%, the underlying financial ratios suggest that the stock is not supported by fundamental value, reinforcing the conclusion that it is overvalued.

What is the technical trend for Oxygenta Pharma?

As of May 12, 2025, Oxygenta Pharma's trend has shifted to bullish, supported by positive weekly MACD and KST indicators, although caution is advised due to a bearish monthly RSI, despite a strong 1Y return of 274.62%.

As of 12 May 2025, the technical trend for Oxygenta Pharma has changed from mildly bullish to bullish. The weekly MACD and KST are both bullish, supporting the bullish stance. The daily moving averages also indicate a bullish trend. However, the monthly RSI is bearish, which suggests some caution. Overall, the strength of the bullish trend is reinforced by the performance metrics, with significant returns over various periods, particularly the 1Y return of 274.62%.

What does Oxygenta Pharma do?

Oxygenta Pharmaceutical Ltd manufactures pharmaceutical preparations and organic fine chemicals, classified as a Micro Cap company. As of March 2025, it reported net sales of 495 Cr and a net loss of 22 Cr.

Overview:<BR>Oxygenta Pharmaceutical Ltd is engaged in the manufacturing of various classes of drugs, including pharmaceutical preparations and organic fine chemicals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Oxygenta Pharmaceutical Ltd was incorporated in 1990 as a Private Limited Company and converted into a Limited Company in 1993. The company changed its name from S.S. Organics Ltd. to Oxygenta Pharmaceutical Limited in the fiscal year 2021-22. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 495 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -22 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 412 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.42 <BR>Return on Equity: 39.08% <BR>Price to Book: -15.74 <BR><BR>Contact Details:<BR>Address: Survey No 252/1 Aroor Village, Sadasivapet Mandal Medak Telangana : 502291 <BR>Tel: 91-08455-250080/250280 <BR>Email: info@ssorganics.co.in <BR>Website: http://oxygentapharma.com

Who are the top shareholders of the Oxygenta Pharma?

The top shareholders of Oxygenta Pharma are M V S Prasad Reddy with 25.56%, and Sravani Reddy Gantla as the highest public shareholder at 12.13%. Individual investors own 43.93%, with no pledged promoter holdings or foreign institutional investors involved.

The top shareholders of Oxygenta Pharma include M V S Prasad Reddy, who holds the largest stake at 25.56%. The highest public shareholder is Sravani Reddy Gantla, with a holding of 12.13%. Additionally, individual investors collectively own 43.93% of the company. There are no pledged promoter holdings, and the company does not have any foreign institutional investors (FIIs) involved.

When is the next results date for Oxygenta Pharma?

Oxygenta Pharma will announce its results on 07 November 2025.

Oxygenta Pharma is scheduled to declare its results on 07 November 2025.

Are Oxygenta Pharma latest results good or bad?

Oxygenta Pharma's latest results are concerning, showing a net loss of ₹6.11 crores and a 69.42% drop in revenue from the previous quarter, indicating severe operational challenges and a negative net worth of ₹25.02 crores. Overall, these results are bad and suggest a critical need for restructuring.

Oxygenta Pharma's latest results are quite concerning. In Q2 FY26, the company reported a net loss of ₹6.11 crores, which is a significant deterioration compared to the previous quarter, reflecting a staggering 349.63% decline quarter-on-quarter. Revenue also dropped sharply by 69.42% from ₹49.47 crores in Q1 FY26 to just ₹15.13 crores, despite a year-on-year growth of 19.89%.<BR><BR>The operating margin has plunged to -45.14%, marking the worst performance in seven quarters, indicating severe operational challenges. Additionally, the profit after tax (PAT) margin fell to -40.38%, worsening from -4.35% in the previous quarter.<BR><BR>Overall, these results highlight a company in acute financial distress, with significant revenue volatility and a negative net worth of ₹25.02 crores. The financial trajectory suggests fundamental issues that could jeopardize its long-term viability. Therefore, the latest results can be characterized as bad, reflecting a critical need for restructuring and operational improvement.

Should I buy, sell or hold Oxygenta Pharma?

How has been the historical performance of Oxygenta Pharma?

Oxygenta Pharma experienced significant sales growth, reaching 109.30 Cr in March 2025, but faced rising expenditures leading to negative operating profit of -10.00 Cr and worsening profitability metrics. Total liabilities increased to 72.62 Cr, with negative shareholder's funds at -25.02 Cr, indicating ongoing financial distress despite a slight improvement in cash flow from operations.

Answer:<BR>The historical performance of Oxygenta Pharma shows significant fluctuations in its financial metrics over the years, with a notable increase in net sales in March 2025 reaching 109.30 Cr, up from 39.64 Cr in March 2024 and 30.99 Cr in March 2023. However, the company has faced challenges with total expenditure, which rose to 119.30 Cr in March 2025 from 49.34 Cr in March 2024, leading to an operating profit of -10.00 Cr in March 2025, slightly worse than -9.70 Cr in the previous year. The profit before tax also declined to -14.35 Cr in March 2025 from -13.87 Cr in March 2024, while the profit after tax was -10.30 Cr, worsening from -3.48 Cr in March 2024. The company's total liabilities increased to 72.62 Cr in March 2025 from 54.46 Cr in March 2024, with total debt at 62.23 Cr. Shareholder's funds remained negative at -25.02 Cr in March 2025, indicating ongoing financial distress. Cash flow from operating activities showed a slight improvement to 2.00 Cr in March 2025, compared to -13.00 Cr in March 2024, but cash flow from investing activities was negative at -11.00 Cr.<BR><BR>Breakdown:<BR>Oxygenta Pharma's financial trajectory reflects a complex mix of growth and challenges. The company's net sales surged to 109.30 Cr in March 2025, a significant increase from previous years, yet this growth was overshadowed by a sharp rise in total expenditure, which reached 119.30 Cr, resulting in an operating profit of -10.00 Cr. This trend continued with a profit before tax of -14.35 Cr and a profit after tax of -10.30 Cr, indicating deteriorating profitability. The total liabilities climbed to 72.62 Cr, with total debt at 62.23 Cr, while shareholder's funds remained negative at -25.02 Cr, highlighting ongoing financial difficulties. Despite a positive cash flow from operating activities of 2.00 Cr, the overall financial health of Oxygenta Pharma appears precarious as it navigates through these challenges.

Which are the latest news on Oxygenta Pharma?

Why is Oxygenta Pharma falling/rising?

As of 03-Dec, Oxygenta Pharmaceutical Ltd's stock price is at Rs 58.80, down 4.08%, and has significantly underperformed its sector. The stock has seen a year-to-date decline of 32.78%, trading below its moving averages, and experiencing reduced investor interest.

As of 03-Dec, Oxygenta Pharmaceutical Ltd's stock price is falling, currently at Rs 58.80, which reflects a decrease of Rs 2.5 or 4.08%. The stock has underperformed its sector by 4.07% today. Although it opened with a gain of 2.72%, it quickly reached a day's high of Rs 62.97 before dropping to a low of Rs 58.6, indicating significant volatility within the trading session.<BR><BR>The stock's performance over the past week shows a decline of 2.00%, while it has decreased by 9.36% over the past month. Year-to-date, the stock has fallen by 32.78%, contrasting sharply with the Sensex, which has gained 8.92% during the same period. This trend of underperformance is further reflected in the stock's long-term returns, with a 1-year decline of 31.51% compared to the Sensex's 5.27% increase.<BR><BR>Additionally, Oxygenta Pharma is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. Furthermore, there has been a notable decline in investor participation, with delivery volume dropping by 89.24% against the 5-day average, indicating reduced interest from investors. Overall, these factors contribute to the stock's current downward trajectory.